17-Jul-2026
Oppenheimer Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)
TipRanks (Tue, 14-Jul 9:25 AM ET)
TipRanks (Tue, 14-Jul 5:50 AM ET)
Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition
TipRanks (Mon, 13-Jul 5:08 PM ET)
Tarsus Pharmaceuticals commercial chief leaves company
Seeking Alpha News (Mon, 13-Jul 4:21 PM ET)
Globe Newswire (Mon, 13-Jul 4:05 PM ET)
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD) and Tarsus Pharmaceuticals (TARS)
TipRanks (Mon, 13-Jul 10:50 AM ET)
Guggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)
TipRanks (Mon, 13-Jul 10:45 AM ET)
Globe Newswire (Wed, 8-Jul 4:05 PM ET)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Globe Newswire (Tue, 2-Jun 8:30 AM ET)
Tarsus to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 28-May 4:30 PM ET)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals trades on the NASDAQ stock market under the symbol TARS.
As of July 17, 2026, TARS stock price climbed to $59.85 with 911,019 million shares trading.
TARS has a beta of 0.04, meaning it tends to be less sensitive to market movements. TARS has a correlation of 0.00 to the broad based SPY ETF.
TARS has a market cap of $2.61 billion. This is considered a Mid Cap stock.
Last quarter Tarsus Pharmaceuticals reported $162 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.23.
In the last 3 years, TARS traded as high as $85.25 and as low as $12.57.
The top ETF exchange traded funds that TARS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
TARS has outperformed the market in the last year with a return of +44.6%, while the SPY ETF gained +19.5%. However, in the most recent history, TARS shares have underperformed the stock market with its stock returning -11.0% in the last 3 month period and -8.5% for the last 2 week period, while SPY has returned +4.9% and -0.2%, respectively.
TARS support price is $55.39 and resistance is $59.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARS shares will trade within this expected range on the day.
